ADVANCED ACCELERATOR APPLICATIONS
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Advanced Accelerator Applications
- Registration Number
- NCT04825652
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 164
- Registration Number
- NCT04727723
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, Italy
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 11
- Registration Number
- NCT04711135
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇫🇷Centre Léon Berard, Lyon, France
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 42
- Registration Number
- NCT04524442
- Locations
- 🇮🇹
Istituto Europero di Oncologia, Milan, MI, Italy
🇳🇱Erasmus University Medical Center, Rotterdam, GD, Netherlands
🇵🇱Gammed-Centrum Diagnostyczno-Lecznicze, Warsaw, Poland
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 226
- Registration Number
- NCT03972488
- Locations
- 🇩🇪
Universitätsklinikum Essen - Klinik für Nuklearmedizin, Essen, Germany
🇬🇧Guys And St Thomas Hospital, London, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 51
- Registration Number
- NCT03872778
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 19
- Registration Number
- NCT03724253
- Locations
- 🇦🇹
Medical University Innsbruck Department of Nuclear Medicine, Innsbruck, Austria
🇫🇷University of Grenoble - Hopital Michallon, Service de Medicine Nucleaire, La Tronche, France
🇫🇷University of Bordeaux, Unite TEP RECHERCHE - Hopital Xavier Arnozan, Pessac, France
Post-Authorization Long-Term Safety Study of LUTATHERA
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 1014
- Registration Number
- NCT03691064
- Locations
- 🇬🇧
Novartis Investigative site, Scheffield, United Kingdom
🇺🇸Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
🇺🇸Virginia Mason in Seattle, Seattle, Washington, United States
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 30
- Registration Number
- NCT03490032
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Pheonix Molecular Imaging Center, Phoenix, Arizona, United States
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 27
- Registration Number
- NCT03490838
- Locations
- 🇺🇸
John Hopkins University - Kimmel Comp. Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Wisconsin / Paul P. Carbone Comp Cancer Center, Madison, Wisconsin, United States
🇺🇸University of California San Francisco, San Francisco, California, United States